Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Dec:3:1-20.
doi: 10.1200/PO.19.00072.

Telomerase Is a Prognostic Marker of Poor Outcome and a Therapeutic Target in Neuroblastoma

Andrea Roderwieser  1   2 , Frederik Sand  1 , Esther Walter  1 , Janina Fischer  1 , Judith Gecht  1 , Christoph Bartenhagen  1   2 , Sandra Ackermann  1   2 , Felix Otte  1 , Anne Welte  1   2 , Yvonne Kahlert  1   2 , Daniela Lieberz  1 , Falk Hertwig  3 , H Christian Reinhardt  2   4 , Thorsten Simon  1 , Martin Peifer  2 , Monika Ortmann  2 , Reinhard Büttner  2 , Barbara Hero  1 , Roderick J O'Sullivan  5 , Frank Berthold  1 , Matthias Fischer  1   2
Affiliations

Telomerase Is a Prognostic Marker of Poor Outcome and a Therapeutic Target in Neuroblastoma

Andrea Roderwieser et al. JCO Precis Oncol. 2019 Dec.

Abstract

Purpose: Telomere maintenance is a hallmark of high-risk neuroblastoma; however, the contribution of telomerase and alternative lengthening of telomeres (ALT) to clinical phenotypes has remained unclear. We aimed to determine the clinical relevance of telomerase activation versus ALT as biomarkers in pretreatment neuroblastoma and to assess the potential value of telomerase as a therapeutic target.

Materials and methods: The genomic status of TERT and MYCN was assessed in 457 pretreatment neuroblastomas by fluorescence in situ hybridization. ALT was examined in 273 of 457 tumors by detection of ALT-associated promyelocytic leukemia nuclear bodies, and TERT expression was determined by microarrays in 223 of these. Cytotoxic effects of telomerase-interacting compounds were analyzed in neuroblastoma cell lines in vitro and in vivo.

Results: We detected TERT rearrangements in 46 of 457 cases (10.1%), MYCN amplification in 93 of 457 cases (20.4%), and elevated TERT expression in tumors lacking TERT or MYCN alterations in 10 of 223 cases (4.5%). ALT activation was found in 49 of 273 cases (17.9%). All these alterations occurred almost mutually exclusively and were associated with unfavorable prognostic variables and adverse outcome. The presence of activated telomerase (ie, TERT rearrangements, MYCN amplification, or high TERT expression without these alterations) was associated with poorest overall survival and was an independent prognostic marker in multivariable analyses. We also found that the telomerase-interacting compound 6-thio-2'-deoxyguanosine effectively inhibited viability and proliferation of neuroblastoma cells bearing activated telomerase. Similarly, tumor growth was strongly impaired upon 6-thio-2'-deoxyguanosine treatment in telomerase-positive neuroblastoma xenografts in mice.

Conclusion: Our data suggest telomerase activation and ALT define distinct neuroblastoma subgroups with adverse outcome and that telomerase may represent a promising therapeutic target in many high-risk neuroblastomas.

PubMed Disclaimer

LinkOut - more resources